AstraZeneca reported “surprise” Phase 3 success for tozorakimab in chronic obstructive pulmonary disease (COPD), winning in two trials—Oberon and Titania—by meeting the main goal of reducing flare-ups. The antibody targets IL-33, aiming to reduce inflammation and mucus-related airway obstruction. AstraZeneca said results spanned former and current smokers and patients across eosinophil counts and lung-function severity. The company also noted it will disclose complete data at an upcoming medical meeting, leaving key details—such as effect sizes and safety—still to be scrutinized. The readout changes the competitive outlook for IL-33-pathway strategies after prior late-stage setbacks in similar approaches, while strengthening AstraZeneca’s pathway to potentially broaden the biologics addressable population in COPD.